Psychiatr. praxi 2017; 18(2e) [Onkologie. 2017:11(1):29-33]

Rational use of psychotropic drugs in oncology – selected indications, interactions, tips for practice

Jana Gregorová1, 2, Petra Holečková3, 4
1 Oddělení klinické farmacie, Nemocnice Na Bulovce, Praha
2 Ústav aplikované farmacie, Farmaceutická fakulta VFU, Brno
3 Ústav radiační onkologie, Nemocnice Na Bulovce, Praha
4 1. lékařská fakulta UK, Praha

Indications psychotropic drugs in oncology include also chemotherapy-induced neuropathy, delirium, nausea, emesis and affect appetite. Psychotropicdrugs are often used "off label" and should be used in patients to attention. Levels of some of psychotropic drugs may be affected by a number of concomitantly administered drugs due to pharmacokinetic drug interactions. Dexamethasone, phenytoin, and carbamazepineare often the co-medication with the above-mentioned indications, among the important enzyme inducers and may reduce the effect ofpsychotropic drugs. Combinations of psychotropics potentially increased risk of pharmacodynamic drug interactions.

Keywords: psychotropic drugs, onkology, drug interaction

Published: July 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gregorová J, Holečková P. Rational use of psychotropic drugs in oncology – selected indications, interactions, tips for practice. Psychiatr. praxi. 2017;18(E-verze 2/17):.
Download citation

References

  1. Hershman DL, Lacchetti CH, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014; 32: 1941-1967. Go to original source... Go to PubMed...
  2. Breitbart W, Alici Y. Evidence-Based Treatment of Delirium in Patients With Cancer. J Clin Oncol. 2012; 30: 1206-1214. Go to original source... Go to PubMed...
  3. Yoon HJ, Park KM, et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry. 2013; 13: 240. Go to original source... Go to PubMed...
  4. Gordon P, LeGrand SB, et al. Nausea and vomiting in advanced cancer. European Journal of Pharmacology 2014; 722: 187-191. Go to original source... Go to PubMed...
  5. Glare P, Miller J, Nikolova T, et al. Treating nausea and vomiting in palliative care: a review. Clinical Interventions in Aging. 2011; 6: 243-259. Go to original source... Go to PubMed...
  6. Hardy JR, O'Shea A, et al. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manage. 2010; 40(1): 111-116. Go to original source... Go to PubMed...
  7. Prommer E. Role of haloperidol in palliative medicine: an update. Am J Hosp Palliat Care. 2012; 29(4): 295-301. Go to original source... Go to PubMed...
  8. Navari RM, Gray SE, et al. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011; 9(5): 188-195. Go to original source... Go to PubMed...
  9. Navari RM, Nagy CK, et al. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Cate Cancer. 2013; 21(6): 1655-1663. Go to original source... Go to PubMed...
  10. Fujáková M, Kopeček M. Antidepresiva - od teorie ke klinické praxi. Klin Farmakol Farm 2012; 26(1): 29-37.
  11. Prokeš M, Suchopár J. Lékové interakce v psychiatrii - teorie a praxe. Psychiatrie pro praxi. 2015; 16(2): 51-56.
  12. Wojcikowski J, Basinska A, et al. The influence of amitriptyline and carbamazepine on levomepromazine metabolism in human liver: An in vitro study. Pharmacological Reports. 2014; 66: 1122-1126. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.